Malcolm Moore - Concepedia

Author

Malcolm Moore

Princess Margaret Cancer Centre ORCID

Also Known As

M L Moore, M Moore, M. Moore, Malcolm Moore, Melissa Moore

Publications

Citations

H-Index

Concepts

All Affiliations

Princess Margaret Cancer Centre

About

Malcolm Moore is an author at Princess Margaret Cancer Centre specializing in oncology, cancer therapeutics, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	142
2	Health Sciences	2	2	68
3	Engineering	1	1	50
4	Emergency Medicine	1	1	50
5	Molecular Medicine	1	1	10

Malcolm Moore

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer Daniel J. Sargent, Silvia Marsoni, Geneviève Monges, Journal of Clinical Oncology	2010	1.6K
No Association Between Hepatitis C and B–Cell Lymphoma Jane Collier, Brent W. Zanke, Malcolm Moore, Hepatology	1999	114
ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma John P. Neoptolemos, Markus W. Büchler, Deborah Stocken, Journal of Clinical Oncology Surgical OncologyCancer ManagementPathologyMay 30Oncology	2009	73
ECG-gated emission computed tomography of the cardiac blood pool. Malcolm Moore, Paul H. Murphy, John A. Burdine Radiology Cross SectionEngineeringBlood FlowElectrophysiological EvaluationImage Analysis	1980	50
Multicenter Phase II Study of Brequinar Sodium in Patients with Advanced Breast Cancer Robert L. Cody, David Stewart, Marcel DeForni, American Journal of Clinical Oncology	1993	45
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours Tara Baetz, Elizabeth A. Eisenhauer, Lillian L. Siu, Investigational New Drugs OncologyMedicineSolid TumoursRadiopharmaceutical TherapyOral Ly293111	2006	30
Clinical experience with gemcitabine in pancreatic carcinoma. M Michael, Malcolm Moore PubMed Advanced Pancreatic CarcinomaPancreatic CancerWeight LossClinical Benefit ResponseGastrointestinal Oncology	1997	18
A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer Janet S. Rader, D. Clarke-Pearson, Malcolm Moore, Gynecologic Oncology MedicineCancer ManagementGynecologyPhase Ii StudyIntravenous Zd9331	2003	11
Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC). Maeve A. Lowery, David P. Kelsen, Malcolm Moore, Journal of Clinical Oncology PathologyPharmacotherapyPancreatic CancerAnti-cancer AgentRadiation Oncology	2015	10

Page 1